The abstract is read at the publisher; the summary is JClub's.
Daptomycin dosing guidance for enterococcal bloodstream infection and endocarditis is misaligned across CLSI and EUCAST, risking underdosing despite evidence supporting 10–12 mg/kg/day in vancomycin-resistant Enterococcus faecium.
- Why it matters: Regulatory and susceptibility interpretation differences can produce inconsistent clinical decisions, and current testing limits reliable MIC-driven dosing, potentially undermining pharmacodynamic target attainment.
- What they did: The work reconciles randomized-trial and susceptibility guidance, highlighting CLSI breakpoints (≤4 mg/L for E. faecium and ≤2 mg/L for E. faecalis) versus EUCAST’s lack of clinical breakpoint, and synthesizes observational dosing–outcome links.
- The result: Observational data associate 10–12 mg/kg/day with lower mortality in vancomycin-resistant E. faecium, motivating a pragmatic MIC-informed dosing framework (≥8 mg/kg/day for E. faecium, 10–12 mg/kg/day in vancomycin-resistant disease) plus β-lactam combination for endocarditis and weekly creatine phosphokinase monitoring.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.